

BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

In the Matter of the First Amended  
Accusation Against:

**Mark Scheier, M.D.**

Physician's and Surgeon's  
Certificate No. A 36345

Respondent.

Case No: 800-2019-057710


**ORDER CORRECTING NUNC PRO TUNC  
MISTAKE OR CLERICAL ERROR IN DECISION**

On its own motion, the Medical Board of California (hereafter "Board") finds that there is a mistake or clerical error in the Decision in the above-entitled matter and that such mistake or clerical error should be corrected.

IT IS HEREBY ORDERED that the Decision in the above-entitled matter be and hereby is amended and corrected, pursuant to Government Code section 11518.5, subdivision (d), as follows:

1. Page 4, line 15: "800-2019-057710" is amended and corrected to read "800-2017-031603".
2. Page 4, line 27: "800-2019-057710" is amended and corrected to read "800-2017-031603".

IT IS SO ORDERED February 10, 2023



Richard E. Thorp, M.D.  
Chair  
Panel B

BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA

In the Matter of the First Amended  
Accusation Against:

Mark Scheier, M.D.

Physician's and Surgeon's  
Certificate No. A 36345

Respondent.

Case No.: 800-2019-057710


DECISION

The attached Stipulated Settlement and Disciplinary Order is hereby adopted as the Decision and Order of the Medical Board of California, Department of Consumer Affairs, State of California.

This Decision shall become effective at 5:00 p.m. on February 24, 2023.

IT IS SO ORDERED: January 26, 2023.

MEDICAL BOARD OF CALIFORNIA



---

Richard E. Thorp, M.D., Chair  
Panel B

1 ROB BONTA  
Attorney General of California  
2 MATTHEW M. DAVIS  
Supervising Deputy Attorney General  
3 GIOVANNI F. MEJIA  
Deputy Attorney General  
4 State Bar No. 309951  
600 West Broadway, Suite 1800  
5 San Diego, CA 92101  
P.O. Box 85266  
6 San Diego, CA 92186-5266  
Telephone: (619) 738-9072  
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

9  
10 **BEFORE THE**  
**MEDICAL BOARD OF CALIFORNIA**  
11 **DEPARTMENT OF CONSUMER AFFAIRS**  
12 **STATE OF CALIFORNIA**

13 In the Matter of the First Amended Accusation  
Against:

14 **MARK SCHEIER, M.D.**  
15 **5451 La Palma Avenue, Ste. 22**  
16 **La Palma, CA 90623**

17 **Physician's and Surgeon's Certificate**  
18 **No. A 36345,**

Respondent.

Case No. 800-2019-057710

OAH No. 2022090568

**STIPULATED SETTLEMENT AND  
DISCIPLINARY ORDER**

19  
20 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-  
21 entitled proceedings that the following matters are true:

22 **PARTIES**

23 1. William Prasifka (Complainant) is the Executive Director of the Medical Board of  
24 California (Board). He brought this action solely in his official capacity and is represented in this  
25 matter by Rob Bonta, Attorney General of the State of California, by Giovanni F. Mejia, Deputy  
26 Attorney General.

27 ///

28 ///





1 **ADDITIONAL PROVISIONS**

2 13. This Stipulated Settlement and Disciplinary Order is intended by the parties herein to  
3 be an integrated writing representing the complete, final and exclusive embodiment of the  
4 agreements of the parties in the above-entitled matter.

5 14. The parties understand and agree that Portable Document Format (PDF) and facsimile  
6 copies of this Stipulated Settlement and Disciplinary Order, including PDF and facsimile  
7 signatures thereto, shall have the same force and effect as the originals.

8 15. In consideration of the foregoing admissions and stipulations, the parties agree that  
9 the Board may, without further notice or opportunity to be heard by the Respondent, issue and  
10 enter the following Disciplinary Order:

11 **DISCIPLINARY ORDER**

12 IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. A 36345 issued  
13 to Respondent Mark Scheier, M.D. is revoked. However, the revocation is stayed and Respondent  
14 is placed on a period of probation to run concurrent with the existing probation term previously  
15 ordered in Medical Board case No. 800-2019-057710, with the following additional terms and  
16 conditions:

17 1. **EDUCATION COURSE.** Within 60 calendar days of the effective date of this  
18 Decision, and on an annual basis thereafter, Respondent shall submit to the Board or its designee  
19 for its prior approval educational program(s) or course(s) which shall not be less than 20 hours  
20 per year, for each year of probation. The educational program(s) or course(s) shall be aimed at  
21 correcting any areas of deficient practice or knowledge and shall be Category I certified. The  
22 educational program(s) or course(s) shall be at Respondent's expense and shall be in addition to  
23 the Continuing Medical Education (CME) requirements for renewal of licensure. Following the  
24 completion of each course, the Board or its designee may administer an examination to test  
25 Respondent's knowledge of the course. Respondent shall provide proof of attendance for 85  
26 hours of CME of which 20 hours were in satisfaction of this condition (and of which 40 hours  
27 were in satisfaction of condition 3 of Board Decision and Order No. 800-2019-057710).

28 ///

1           2.    NOTIFICATION. Within seven (7) days of the effective date of this Decision, the  
2 Respondent shall provide a true copy of this Decision and Accusation to the Chief of Staff or the  
3 Chief Executive Officer at every hospital where privileges or membership are extended to  
4 Respondent, at any other facility where Respondent engages in the practice of medicine,  
5 including all physician and locum tenens registries or other similar agencies, and to the Chief  
6 Executive Officer at every insurance carrier which extends malpractice insurance coverage to  
7 Respondent. Respondent shall submit proof of compliance to the Board or its designee within 15  
8 calendar days.

9           This condition shall apply to any change(s) in hospitals, other facilities or insurance carrier.

10           3.    SUPERVISION OF PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE  
11 NURSES. During probation, Respondent is prohibited from supervising physician assistants and  
12 advanced practice nurses.

13           4.    OBEY ALL LAWS. Respondent shall obey all federal, state and local laws, all rules  
14 governing the practice of medicine in California and remain in full compliance with any court  
15 ordered criminal probation, payments, and other orders.

16           5.    INVESTIGATION/ENFORCEMENT COST RECOVERY. Respondent is hereby  
17 ordered to reimburse the Board its costs of investigation and enforcement, including, but not  
18 limited to, expert review, amended accusations, legal reviews, and investigation(s), as applicable,  
19 in the amount of \$20,000 (twenty thousand dollars). Costs shall be payable to the Medical Board  
20 of California. Failure to pay such costs shall be considered a violation of probation.

21           Payment must be made in full within one year of the effective date of the Order, or by a  
22 payment plan approved by the Medical Board of California. Any and all requests for a payment  
23 plan shall be submitted in writing by respondent to the Board. Failure to comply with the payment  
24 plan shall be considered a violation of probation.

25           The filing of bankruptcy by respondent shall not relieve respondent of the responsibility to  
26 repay investigation and enforcement costs, including expert review costs.

27    ////

28    ////

1           6.    QUARTERLY DECLARATIONS. Respondent shall submit quarterly declarations  
2 under penalty of perjury on forms provided by the Board, stating whether there has been  
3 compliance with all the conditions of probation.

4           Respondent shall submit quarterly declarations not later than 10 calendar days after the end  
5 of the preceding quarter.

6           7.    GENERAL PROBATION REQUIREMENTS.

7           Compliance with Probation Unit

8           Respondent shall comply with the Board's probation unit.

9           Address Changes

10          Respondent shall, at all times, keep the Board informed of Respondent's business and  
11 residence addresses, email address (if available), and telephone number. Changes of such  
12 addresses shall be immediately communicated in writing to the Board or its designee. Under no  
13 circumstances shall a post office box serve as an address of record, except as allowed by Business  
14 and Professions Code section 2021, subdivision (b).

15          Place of Practice

16          Respondent shall not engage in the practice of medicine in Respondent's or patient's place  
17 of residence, unless the patient resides in a skilled nursing facility or other similar licensed  
18 facility.

19          License Renewal

20          Respondent shall maintain a current and renewed California physician's and surgeon's  
21 license.

22          Travel or Residence Outside California

23          Respondent shall immediately inform the Board or its designee, in writing, of travel to any  
24 areas outside the jurisdiction of California which lasts, or is contemplated to last, more than thirty  
25 (30) calendar days.

26          In the event Respondent should leave the State of California to reside or to practice  
27 Respondent shall notify the Board or its designee in writing 30 calendar days prior to the dates of  
28 departure and return.



1           8.    INTERVIEW WITH THE BOARD OR ITS DESIGNEE. Respondent shall be  
2 available in person upon request for interviews either at Respondent’s place of business or at the  
3 probation unit office, with or without prior notice throughout the term of probation.

4           9.    NON-PRACTICE WHILE ON PROBATION. Respondent shall notify the Board or  
5 its designee in writing within 15 calendar days of any periods of non-practice lasting more than  
6 30 calendar days and within 15 calendar days of Respondent’s return to practice. Non-practice is  
7 defined as any period of time Respondent is not practicing medicine as defined in Business and  
8 Professions Code sections 2051 and 2052 for at least 40 hours in a calendar month in direct  
9 patient care, clinical activity or teaching, or other activity as approved by the Board. If  
10 Respondent resides in California and is considered to be in non-practice, Respondent shall  
11 comply with all terms and conditions of probation. All time spent in an intensive training program  
12 which has been approved by the Board or its designee shall not be considered non-practice and  
13 does not relieve Respondent from complying with all the terms and conditions of probation.  
14 Practicing medicine in another state of the United States or Federal jurisdiction while on  
15 probation with the medical licensing authority of that state or jurisdiction shall not be considered  
16 non-practice. A Board-ordered suspension of practice shall not be considered as a period of non-  
17 practice.

18           In the event Respondent’s period of non-practice while on probation exceeds 18 calendar  
19 months, Respondent shall successfully complete the Federation of State Medical Boards’s Special  
20 Purpose Examination, or, at the Board’s discretion, a clinical competence assessment program  
21 that meets the criteria of Condition 18 of the current version of the Board’s “Manual of Model  
22 Disciplinary Orders and Disciplinary Guidelines” prior to resuming the practice of medicine.

23           Respondent’s period of non-practice while on probation shall not exceed two (2) years.

24           Periods of non-practice will not apply to the reduction of the probationary term.

25           Periods of non-practice for a Respondent residing outside of California will relieve  
26 Respondent of the responsibility to comply with the probationary terms and conditions with the  
27 exception of this condition and the following terms and conditions of probation: Obey All Laws;

28    ///

1 General Probation Requirements; Quarterly Declarations; Abstain from the Use of Alcohol and/or  
2 Controlled Substances; and Biological Fluid Testing.

3 10. COMPLETION OF PROBATION. Respondent shall comply with all financial  
4 obligations (e.g., restitution, probation costs) not later than 120 calendar days prior to the  
5 completion of probation. This term does not include cost recovery, which is due within 30  
6 calendar days of the effective date of the Order, or by a payment plan approved by the Medical  
7 Board and timely satisfied. Upon successful completion of probation, Respondent's certificate  
8 shall be fully restored.

9 11. VIOLATION OF PROBATION. Failure to fully comply with any term or condition  
10 of probation is a violation of probation. If Respondent violates probation in any respect, the  
11 Board, after giving Respondent notice and the opportunity to be heard, may revoke probation and  
12 carry out the disciplinary order that was stayed. If an Accusation, or Petition to Revoke Probation,  
13 or an Interim Suspension Order is filed against Respondent during probation, the Board shall have  
14 continuing jurisdiction until the matter is final, and the period of probation shall be extended until  
15 the matter is final.

16 12. LICENSE SURRENDER. Following the effective date of this Decision, if  
17 Respondent ceases practicing due to retirement or health reasons or is otherwise unable to satisfy  
18 the terms and conditions of probation, Respondent may request to surrender his or her license.  
19 The Board reserves the right to evaluate Respondent's request and to exercise its discretion in  
20 determining whether or not to grant the request, or to take any other action deemed appropriate  
21 and reasonable under the circumstances. Upon formal acceptance of the surrender, Respondent  
22 shall within 15 calendar days deliver Respondent's wallet and wall certificate to the Board or its  
23 designee and Respondent shall no longer practice medicine. Respondent will no longer be subject  
24 to the terms and conditions of probation. If Respondent re-applies for a medical license, the  
25 application shall be treated as a petition for reinstatement of a revoked certificate.

26 13. PROBATION MONITORING COSTS. Respondent shall pay the costs associated  
27 with probation monitoring each and every year of probation, as designated by the Board, which  
28 may be adjusted on an annual basis. Such costs shall be payable to the Medical Board of

1 California and delivered to the Board or its designee no later than January 31 of each calendar  
2 year.

3 14. FUTURE ADMISSIONS CLAUSE. If Respondent should ever apply or reapply for a  
4 new license or certification, or petition for reinstatement of a license, before any other health care  
5 licensing agency in the State of California, all of the charges and allegations contained in First  
6 Amended Accusation No. 800-2019-057710 shall be deemed to be true, correct, and admitted by  
7 Respondent for the purpose of any Statement of Issues or any other proceeding seeking to deny or  
8 restrict a license.

9 ////

10 ////

11 ////

12 ////

13 ////

14 ////

15 ////

16 ////

17 ////

18 ////

19 ////

20 ////

21 ////

22 ////

23 ////

24 ////

25 ////

26 ////

27 ////

28 ////


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**ACCEPTANCE**

I have carefully read the above Stipulated Settlement and Disciplinary Order and have fully discussed it with my attorney, Raymond J. McMahon. I understand the stipulation and the effect it will have on my Physician's and Surgeon's Certificate. I enter into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Medical Board of California.

DATED: 11/11/22   
MARK SCHEIER, M.D.  
*Respondent*

I have read and fully discussed with Respondent Mark Scheier, M.D. the terms and conditions and other matters contained in the above Stipulated Settlement and Disciplinary Order. I approve its form and content.


DATED: November 11, 2022   
RAYMOND J. MCMAHON  
*Attorney for Respondent*

**ENDORSEMENT**

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California.

DATED: November 15, 2022

Respectfully submitted,  
ROB BONTA  
Attorney General of California  
MATTHEW M. DAVIS  
Supervising Deputy Attorney General

  
GIOVANNI F. MEJIA  
Deputy Attorney General  
*Attorneys for Complainant*

SD2022801251/83644692.docx

**Exhibit A**

**First Amended Accusation No. 800-2019-057710**

1 ROB BONTA  
Attorney General of California  
2 MATTHEW M. DAVIS  
Supervising Deputy Attorney General  
3 GIOVANNI F. MEJIA  
Deputy Attorney General  
4 State Bar No. 309951  
600 West Broadway, Suite 1800  
5 San Diego, CA 92101  
P.O. Box 85266  
6 San Diego, CA 92186-5266  
Telephone: (619) 738-9072  
7 Facsimile: (619) 645-2061

8 *Attorneys for Complainant*

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**BEFORE THE  
MEDICAL BOARD OF CALIFORNIA  
DEPARTMENT OF CONSUMER AFFAIRS  
STATE OF CALIFORNIA**

In the Matter of the First Amended Accusation  
Against:  
**Mark Scheier, M.D.**  
**5451 La Palma Avenue, Ste. 22**  
**La Palma, CA 90623**  
**Physician's and Surgeon's**  
**Certificate No. A 36345**  
Respondent.

Case No. 800-2019-057710  
**FIRST AMENDED ACCUSATION**

**PARTIES**

1. William Prasifka (Complainant) brings this First Amended Accusation solely in his official capacity as the Executive Director of the Medical Board of California, Department of Consumer Affairs (Board).
2. On or about February 23, 1981, the Medical Board issued Physician's and Surgeon's Certificate No. A 36345 to Mark Scheier, M.D. (Respondent). The Physician's and Surgeon's Certificate was in full force and effect at all times relevant to the charges brought herein and will expire on May 31, 2024, unless renewed.

///

**JURISDICTION**

1  
2       3.     This First Amended Accusation, which supersedes Accusation No. 800-2019-057710  
3 filed on June 9, 2022 in the above-entitled matter, is brought before the Board, under the authority  
4 of the following laws. All section references are to the Business and Professions Code (Code)  
5 unless otherwise indicated.

6       4.     Section 2227, subdivision (a) of the Code states:

7             A licensee whose matter has been heard by an administrative law judge of the  
8 Medical Quality Hearing Panel as designated in Section 11371 of the Government Code, or  
9 whose default has been entered, and who is found guilty, or who has entered into a  
stipulation for disciplinary action with the board, may, in accordance with the provisions of  
this chapter:

10            (1) Have his or her license revoked upon order of the board.

11            (2) Have his or her right to practice suspended for a period not to exceed one year  
12 upon order of the board.

13            (3) Be placed on probation and be required to pay the costs of probation monitoring  
upon order of the board.

14            (4) Be publicly reprimanded by the board. The public reprimand may include a  
15 requirement that the licensee complete relevant educational courses approved by the board.

16            (5) Have any other action taken in relation to discipline as part of an order of  
probation, as the board or an administrative law judge may deem proper.

17       5.     Section 2234 of the Code states, in pertinent part:

18             The board shall take action against any licensee who is charged with  
19 unprofessional conduct. In addition to other provisions of this article, unprofessional  
conduct includes, but is not limited to, the following:

20             ...

21            (b) Gross negligence.

22            (c) Repeated negligent acts. To be repeated, there must be two or more  
23 negligent acts or omissions. An initial negligent act or omission followed by a  
separate and distinct departure from the applicable standard of care shall constitute  
repeated negligent acts.

24            (1) An initial negligent diagnosis followed by an act or omission medically  
25 appropriate for that negligent diagnosis of the patient shall constitute a single  
negligent act.

26            (2) When the standard of care requires a change in the diagnosis, act, or  
27 omission that constitutes the negligent act described in paragraph (1), including, but  
not limited to, a reevaluation of the diagnosis or a change in treatment, and the

28     ///

1 licensee's conduct departs from the applicable standard of care, each departure  
2 constitutes a separate and distinct breach of the standard of care.....

3 6. Section 2242 of the Code states:

4 (a) Prescribing, dispensing, or furnishing dangerous drugs as defined in  
5 Section 4022 without an appropriate prior examination and a medical indication,  
6 constitutes unprofessional conduct.

6 "..."

7 7. Section 2266 of the Code states: The failure of a physician and surgeon to maintain  
8 adequate and accurate records relating to the provision of services to their patients constitutes  
9 unprofessional conduct.

10 8. Section 725 of the Code states:

11 (a) Repeated acts of clearly excessive prescribing, furnishing, dispensing, or  
12 administering of drugs or treatment, repeated acts of clearly excessive use of  
13 diagnostic procedures, or repeated acts of clearly excessive use of diagnostic or  
14 treatment facilities as determined by the standard of the community of licensees is  
unprofessional conduct for a physician and surgeon, dentist, podiatrist, psychologist,  
physical therapist, chiropractor, optometrist, speech-language pathologist, or  
audiologist.

15 "..."

16 9. Unprofessional conduct under Business and Professions Code section 2234 is conduct  
17 which breaches the rules or ethical code of the medical profession, or conduct which is  
18 unbecoming a member in good standing of the medical profession, and which demonstrates an  
19 unfitness to practice medicine. (*Shea v. Board of Medical Examiners* (1978) 81 Cal.App.3d 564,  
20 575.)

### 21 COST RECOVERY

22 10. Section 125.3 of the Code states:

23 (a) Except as otherwise provided by law, in any order issued in resolution of a  
24 disciplinary proceeding before any board within the department or before the  
25 Osteopathic Medical Board, upon request of the entity bringing the proceeding, the  
26 administrative law judge may direct a licensee found to have committed a violation or  
27 violations of the licensing act to pay a sum not to exceed the reasonable costs of the  
28 investigation and enforcement of the case.

(b) In the case of a disciplined licensee that is a corporation or a partnership, the  
order may be made against the licensed corporate entity or licensed partnership.

28 ///





1 FACTS

2 **Patient A<sup>1</sup>**

3 11. Beginning in or around 2015<sup>2</sup>, Respondent began rendering medical care and  
4 treatment to Patient A, an adult patient with a history of ailments including, but not limited to,  
5 obesity, hypertension,<sup>3</sup> chronic obstructive pulmonary disease (COPD),<sup>4</sup> chronic low back and  
6 hip pain, and current tobacco addiction.

7 ///

8 ///

9 ///

10 ///

11 ///

12 ///

13 ///

14 ///

15 ///

16 ///

17 ///

18 ///

19 ///

20 ///

---

21 <sup>1</sup> Patients' true names are not used in the instant First Amended Accusation to maintain  
22 patient confidentiality. The patients' identities are known to Respondent or will be disclosed to  
23 Respondent upon receipt of a duly issued request for discovery in accordance with Government  
Code section 11507.6.

24 <sup>2</sup> Any act or omission alleged to have occurred more than seven years prior to the filing of  
25 the instant First Amended Accusation is alleged for informational purposes only, and is not  
alleged as a basis for disciplinary action.

26 <sup>3</sup> Hypertension refers to a condition in which the force of the blood against the artery walls  
is too high (high blood pressure).

27 <sup>4</sup> Chronic obstructive pulmonary disease (COPD) is a group of lung diseases that block  
28 airflow and make it difficult to breathe.

1 12. In or around January 2016 through in or around June 30, 2016, Respondent issued  
2 recurring prescriptions for hydrocodone<sup>5</sup> 40 mg daily (MED<sup>6</sup> of 40 mg) with Soma<sup>7</sup> 350 mg 4X  
3 daily.

4 13. In or around October 2017, November 2017, December 2017, January 2018, and  
5 March 2018, Respondent prescribed hydrocodone 40 mg daily (MED of 40 mg) and Soma  
6 350 mg 4X daily.

7 ///

8  
9 <sup>5</sup> Hydrocodone APAP (Vicodin®, Lortab® and Norco®) is a hydrocodone combination of  
10 hydrocodone bitartrate and acetaminophen which was formerly a Schedule III controlled  
11 substance pursuant to Health and Safety Code section 11056, subdivision (e), and a dangerous  
12 drug pursuant to Business and Professions Code section 4022. On August 22, 2014, the DEA  
13 published a final rule rescheduling hydrocodone combination products (HCPs) to schedule II of  
14 the Controlled Substances Act, which became effective October 6, 2014. Schedule II controlled  
15 substances are substances that have a currently accepted medical use in the United States, but also  
16 have a high potential for abuse, and the abuse of which may lead to severe psychological or  
17 physical dependence. When properly prescribed and indicated, it is used for the treatment of  
18 moderate to severe pain. In addition to the potential for psychological and physical dependence  
19 there is also the risk of acute liver failure which has resulted in a black box warning being issued  
20 by the U.S. Food and Drug Administration (FDA). The FDA black box warning provides that  
21 “Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver  
22 transplant and death. Most of the cases of liver injury are associated with use of the  
23 acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one  
24 acetaminophen containing product.”

25 <sup>6</sup> Morphine equivalency dose (MED) is a value assigned to opioids to represent their  
26 relative potencies. MED is determined by using an equivalency factor to calculate a dose of  
27 morphine that is equivalent to the prescribed opioid. Daily MED is the sum total of all opioids,  
28 with conversion factors applied, that are being taken within a 24-hour period, which is used to  
determine if a patient is at risk of addiction, respiratory depression, or other delirious effects  
associated with opioids. The process of converting opioid doses to an overall morphine  
equivalency dose can be accomplished by using a MED calculator or a morphine equivalency  
table, also known as opioid conversion chart.

29 <sup>7</sup> Soma® (carisoprodol) is a Schedule IV controlled substance pursuant to Health and  
30 Safety Code section 11057, subdivision (d), and a dangerous drug pursuant to Business and  
31 Professions Code section 4022. When properly prescribed and indicated, it is used for the short-  
32 term treatment of acute and painful musculoskeletal conditions. Soma® is commonly used by  
33 those who abuse opioids to potentiate the euphoric effect of opioids, to create a better “high.”  
34 According to the DEA, Office of Diversion Control, “[c]arisoprodol abuse has escalated in the  
35 last decade in the United States. According to Diversion Drug Trends, published by the DEA on  
36 the trends in diversion of controlled and noncontrolled pharmaceuticals, carisoprodol continues to  
37 be one of the most commonly diverted drugs. Diversion and abuse of carisoprodol is prevalent  
38 throughout the country. As of March 2011, street prices for [carisoprodol] Soma® ranged from  
\$1 to \$5 per tablet. Diversion methods include doctor shopping for the purposes of obtaining  
multiple prescriptions and forging prescriptions.”

1 14. Between 2017 through 2018, Patient A presented to Respondent frequently for pain  
2 medications and Soma prescription renewals. The clinic notes for these visits lacked any detailed  
3 musculoskeletal and spine examinations of Patient A. The clinic notes consistently showed that  
4 Patient A was wheezing<sup>8</sup> on auscultations.<sup>9</sup>

5 15. In or around late 2018, Respondent added atenolol<sup>10</sup> therapy to Patient A's high blood  
6 pressure medication regimen. However, Patient A still had uncontrolled blood pressure in May  
7 2019 during her follow-up visit.

8 Evaluation and Non-Opiate Management of Chronic Pain

9 16. In or around January 2016 to December 2019, Respondent committed negligence in  
10 the course of his care and treatment of Patient A by failing to request and/or failing to document  
11 having requested Patient A's prior medical records for review and/or confirmation of history of  
12 prior care and/or treatment and/or evaluation of Patient A's total body pains, including, but not  
13 limited to, neck, upper back, and hips, before prescribing hydrocodone and Soma on a regular  
14 basis.

15 17. In or around January 2016 to December 31, 2019, Respondent committed negligence  
16 in the course of his care and treatment of Patient A by failing to adequately utilize and/or failing  
17 to document having adequately utilized non-opiate pain management options, including, but not  
18 limited to, failing to titrate upwards the dosages of gabapentin<sup>11</sup> and tricyclics<sup>12</sup> for pain

19 ///

20 \_\_\_\_\_  
21 <sup>8</sup> Wheeze means (of a person) breathe with a whistling or rattling sound in the chest, as a  
22 result of obstruction in the air passages.

23 <sup>9</sup> Auscultation refers to the action of listening to sounds from the heart, lungs, or other  
24 organs, typically with a stethoscope, as a part of medical diagnosis.

25 <sup>10</sup> Atenolol is a beta blocker, which can be used to treat high blood pressure and chest pain  
26 (angina). It can also reduce the risk of death after a heart attack.

27 <sup>11</sup> Gabapentin is an anticonvulsant and nerve pain medication, which can be used to treat  
28 seizures and pain caused by shingles (a reactivation of the chickenpox virus in the body, causing a  
painful rash).

<sup>12</sup> Tricyclic antidepressants are a class of medications that are used primarily for  
antidepressants, which is important for the management of depression.

1 management, failing to offer safer medications such as NSAIDS,<sup>13</sup> pregabalin,<sup>14</sup> SSRI,<sup>15</sup> non-  
2 addictive muscle relaxants, and topical creams, failing to offer physical therapy or chiropractic  
3 manipulation or surgical orthopedic consultation, and failing to discuss aggressive steps such as  
4 daily exercises and dietary restrictions to achieve weight reduction.

5 Initiation and Monitoring of Chronic Pain Medications

6 18. In or around January 2016 to December 2019, Respondent committed negligence in  
7 the course of his care and treatment of Patient A in that prior to initiating prescribing of chronic  
8 pain medications on a regular basis, Respondent failed to review and/or failed to document  
9 having reviewed Patient A's previous medical records and/or failed to consult and/or failed to  
10 document having consulted former prescribing doctors, before formulating his own independent  
11 judgment regarding prescribing of opiates to Patient A.

12 19. In or around January 2016 to December 2019, Respondent committed negligence in  
13 the course of his care and treatment of Patient A in that prior to initiating prescribing of chronic  
14 pain medications on a regular basis, Respondent failed to properly perform risk stratification  
15 (determining the patient's risk of drug addiction and aberrancy), by failing to, among other things,  
16 perform a psychological evaluation assessing risks of addictive behaviors by using a set of  
17 questionnaire such as Opioid Risk Tool (ORT),<sup>16</sup> SOAPP-R,<sup>17</sup> or PHQ-9,<sup>18</sup> failing to make a  
18 possible referral to psychiatry physicians, if Patient A shows above average risk of addiction, and

19 <sup>13</sup> Nonsteroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to  
20 relieve pain, reduce inflammation, and bring down a high temperature.

21 <sup>14</sup> Pregabalin is a nerve pain medication, which can treat nerve and muscle pain.

22 <sup>15</sup> Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed  
antidepressants.

23 <sup>16</sup> Opioid risk tool (ORT) is a brief, self-report screening tool designed for use with adult  
24 patients in primary care settings to assess risk for opioid abuse among individuals prescribed  
opioids for treatment of chronic pain.

25 <sup>17</sup> The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) is a tool  
26 for clinicians to help determine how much monitoring a patient on long-term opioid therapy  
might require.

27 <sup>18</sup> PHQ-9 (Patient Health Questionnaire – 9) is a multipurpose instrument for screening,  
28 diagnosing, monitoring, and measuring the severity of depression.

1 failing to closely monitor with regular urine drug testing and/or consultations with a state  
2 prescription drug monitoring program (PDMP)<sup>19</sup> such as CURES reports.<sup>20</sup>

3 20. In or around January 2016 to December 2019, Respondent committed negligence in  
4 the course of his care and treatment of Patient A by failing to offer and/or failing to document  
5 having offered a multidisciplinary pain management approach including, but not limited to,  
6 surgical orthopedic consultation, pain management consultation, cognitive behavioral therapy  
7 with mental health, physical therapy, and primary care coordination, which may reduce Patient  
8 A's addiction risks, while adequately treating her pain syndrome.

9 21. In or around January 2016 to December 2019, Respondent committed negligence in  
10 the course of his care and treatment of Patient A by failing to adequately obtain routine regular  
11 urine toxicology testing and/or failing to adequately check CURES reports.

12 22. In or around January 2016 to December 2019, Respondent committed negligence in  
13 the course of his care and treatment of Patient A by failing to prescribe and/or failing to document  
14 having prescribed naloxone<sup>21</sup> antidote to Patient A, a patient with active COPD illness who was  
15 consuming long-term opiates and Soma.

16 23. In or around January 2016 to December 2019, Respondent committed negligence in  
17 the course of his care and treatment of Patient A by failing to perform and/or failing to document  
18 having performed relevant musculoskeletal examinations and functional assessments during  
19 Patient A's visits for narcotic refills.

20 Carisoprodol (Soma) Therapy and Its Indications

21 24. In or around January 2016 to December 2019, Respondent committed negligence in  
22 the course of his care and treatment of Patient A by prescribing Soma to Patient A, on a long-term  
23 basis.

24 \_\_\_\_\_  
25 <sup>19</sup> Prescription Drug Monitoring Program (PDMP) is an electronic database that tracks  
controlled substance prescriptions.

26 <sup>20</sup> CURES is the Controlled Substances Utilization Review and Evaluation System  
27 (CURES), a database of schedule II, III, and IV controlled substance prescriptions dispensed in  
California, serving the public health, regulatory oversight agencies, and law-enforcement.

28 <sup>21</sup> Naloxone is a narcotic, which can treat narcotic overdose in an emergency situation.

1           25. In or around January 2016 to December 2019, Respondent committed negligence in  
2 the course of his care and treatment of Patient A by failing to prescribe naloxone antidote to  
3 Patient A, a patient who was consuming Soma while opiate dependent with an active COPD.

4           Informed Consent and Pain Management Agreement

5           26. In or around January 2016 to December 2019, Respondent committed negligence in  
6 the course of his care and treatment of Patient A by initiating prescribing of chronic pain  
7 medications on a regular basis, without having first obtained adequate informed consent, which  
8 includes, but is not limited to, adequately discussing Patient A's increased risk of accidental  
9 overdose from consuming both opiate and Soma, due to her COPD.

10          27. In or around January 2016 to December 2019, Respondent committed negligence in  
11 the course of his care and treatment of Patient A by initiating prescribing of chronic pain  
12 medications on a regular basis, without having first obtained a pain management agreement with  
13 Patient A.

14           Management of Chronic Obstructive Lung Disease (COPD)

15          28. In or around January 2016 to December 2019, Respondent committed negligence in  
16 the course of his care and treatment of Patient A by failing to properly treat Patient A's COPD  
17 with multiple inhalers.

18          29. In or around January 2016 to December 2019, Respondent committed negligence in  
19 the course of his care and treatment of Patient A by failing to conduct and/or failing to document  
20 having conducted adequate functional assessment(s) in order to determine the severity of  
21 Patient A's COPD.

22          30. In or around January 2016 to December 2019, Respondent committed negligence in  
23 the course of his care and treatment of Patient A by failing to offer and/or failing to document  
24 having offered Patient A medications to help with Patient A's tobacco addiction.

25           Management of Chronic Hypertension

26          31. In or around January 2016 to December 2019, Respondent committed negligence in  
27 the course of his care and treatment of Patient A by failing to take and/or failing to document  
28 having taken more aggressive steps towards management of Patient A's chronic hypertension,

1 including, but not limited to, encouraging Patient A to do home self-monitoring of her blood  
2 pressure readings and sharing them with Respondent, engaging in a serious discussion with  
3 Patient A about weight loss and dietary sodium modifications to improve blood pressure  
4 measurements, and faster titration of Patient A's blood pressure medications.

5 Medical Record-Keeping

6 32. In or around January 2016 to December 2019, Respondent committed negligence in  
7 the course of his care and treatment of Patient A by failing to document relevant musculoskeletal  
8 examination(s), if any, and functional assessment(s), if any, of opiate therapy, and/or by failing to  
9 document his counseling of Patient A regarding lifestyle measures for lowering her blood  
10 pressure, if any, and/or by failing to document having prescribed inhalation therapies for  
11 Patient A's COPD, if any.

12 **Patient B**

13 33. In or around 2014,<sup>22</sup> Respondent began rendering medical care and treatment to  
14 Patient B, an adult patient with a history of ailments including, but not limited to, chronic low  
15 back pain and ADHD.<sup>23</sup>

16 34. In early 2016, a urine toxicology confirmed Patient B's illicit use of marijuana.

17 35. In or around January 2017 through in or around December 2019, Patient B presented  
18 to Respondent on a monthly basis for medication refills and pain management. In 2017,  
19 Respondent prescribed to Patient B, on a monthly basis, hydrocodone mg daily (MED of 40 mg),

20 ///

21 ///

22 ///

23 ///

24 ///

---

25 <sup>22</sup> Conduct occurring more than seven (7) years from the filing date of Accusation No.  
26 800-2019-057710 is for informational purposes only and is not alleged as a basis for disciplinary  
action.

27 <sup>23</sup> Attention-deficit hyperactivity disorder (ADHD) is a chronic condition including  
28 attention difficulty, hyperactivity, and impulsiveness.



1 amphetamine (Adderall)<sup>24</sup> 60-90 mg daily, and alprazolam (Xanax)<sup>25</sup> 6 mg daily. Respondent  
2 prescribed alprazolam to Patient B for generalized anxiety disorder. In 2017, Respondent also  
3 prescribed to Patient B ibuprofen<sup>26</sup> and cyclobenzaprine therapy<sup>27</sup>, without significant benefits.  
4 There were no detailed musculoskeletal examinations and no detailed functional assessment(s) of  
5 the opiate therapy.

6 36. In 2018, Patient B continued to present to Respondent for medication refills. In June  
7 2018, Patient B's alprazolam medication was lowered to 4 mg daily and discontinued in  
8 October 2018.

9 37. In or around January 2019, Respondent prescribed naloxone antidote therapy to  
10 Patient B.

11 38. In or around September 2019, Respondent reduced Patient B's daily hydrocodone  
12 prescription to 15 mg daily (MED of 15 mg).

13 ///

14 ///

15 \_\_\_\_\_  
16 <sup>24</sup> Adderall®, a mixture of d-amphetamine and l-amphetamine salts in a ratio of 3:1, is a  
17 central nervous system stimulant of the amphetamine class, and is a Schedule II controlled  
18 substance pursuant to Health and Safety Code section 11055, subdivision (d), and a dangerous  
19 drug pursuant to Business and Professions Code section 4022. When properly prescribed and  
20 indicated, it is used for attention-deficit hyperactivity disorder and narcolepsy. According to the  
DEA, amphetamines, such as Adderall®, are considered a drug of abuse. "The effects of  
amphetamines and methamphetamine are similar to cocaine, but their onset is slower and their  
duration is longer." (Drugs of Abuse – A DEA Resource Guide (2011), at p. 44.) Adderall and  
other stimulants are contraindicated for patients with a history of drug abuse.

21 <sup>25</sup> Xanax® (alprazolam), a benzodiazepine, is a centrally acting hypnotic-sedative that is a  
22 Schedule IV controlled substance pursuant to Health and Safety Code section 11057, subdivision  
23 (d), and a dangerous drug pursuant to Business and Professions Code section 4022. When  
24 properly prescribed and indicated, it is used for the management of anxiety disorders.  
25 Concomitant use of Xanax® with opioids "may result in profound sedation, respiratory  
depression, coma, and death." The Drug Enforcement Administration (DEA) has identified  
benzodiazepines, such as Xanax®, as a drug of abuse. (Drugs of Abuse, DEA Resource Guide  
(2011 Edition), at p. 53.)

26 <sup>26</sup> Ibuprofen is a nonsteroidal anti-inflammatory drug, which can be used to treat fever and  
mild to severe pain.

27 <sup>27</sup> Cyclobenzaprine is a muscle relaxant, which can be used to treat pain and stiffness  
28 caused by muscle spasms.

1           Management of Generalized Anxiety Disorder

2           39. In or around January 2017 through in or around December 2019, Respondent  
3 committed negligence in the course of his care and treatment of Patient B by failing to perform a  
4 comprehensive anxiety evaluation of Patient B.

5           40. In or around January 2017 through in or around December 2019, Respondent  
6 committed negligence in the course of his care and treatment of Patient B by failing to prescribe  
7 safer and non-addictive anxiolytic medications<sup>28</sup> like SSRI and antihistamines<sup>29</sup> in conjunction  
8 with and/or instead of Adderall.

9           41. In or around January 2017 through in or around December 2019, Respondent  
10 committed negligence in the course of his care and treatment of Patient B by failing to offer  
11 and/or failing to document having offered mental health consultation to Patient B, a patient  
12 consuming Adderall (stimulant medication) with ADHD and co-existing anxiety disorder.

13           Prescribing of amphetamine (Adderall)

14           42. In or around January 2017 through in or around December 2019, Respondent  
15 committed negligence in the course of his care and treatment of Patient B by failing to properly  
16 prescribe Adderall in that he failed to conduct an ADHD screening questionnaire, failed to  
17 confirm with Patient B's previous physicians and/or review prior medical records to determine  
18 validity of self-reported ADHD diagnosis, and failed to conduct detailed review(s) of Patient B's  
19 ADHD symptoms, if any.

20           Evaluation and Non-Opiate Management of Chronic Pains

21           43. In or around January 2017 through in or around December 2019, Respondent  
22 committed negligence in the course of his care and treatment of Patient B by failing to prescribe  
23 safer, non-opiate pharmacotherapy, including, but not limited to, NSAIDs, SSRI, topical creams,  
24 and gabapentin/pregabalin.

25           ///

26           <sup>28</sup> Anxiolytic means (chiefly of a drug) used to reduce anxiety.

27           <sup>29</sup> Antihistamines are medications often used to relieve symptoms of allergies and  
28 reactions to insect bites or stings. They are also used to prevent motion sickness and as a short-  
term treatment for insomnia.

1           44. In or around January 2017 through in or around December 2019, Respondent  
2 committed negligence in the course of his care and treatment of Patient B by failing to consider  
3 and/or failing to document having considered referring Patient B to mental health services for  
4 cognitive behavioral therapy.

5           Initiation and Monitoring of Chronic Opiate Pain Medications

6           45. In or around January 2017 to December 2019, Respondent committed negligence in  
7 the course of his care and treatment of Patient B in that prior to initiating prescribing of chronic  
8 pain medications on a regular basis, Respondent failed to review and/or failed to document  
9 having reviewed Patient B's previous medical records and/or failed to consult and/or failed to  
10 document having consulted former prescribing doctors, before formulating his own independent  
11 judgment regarding prescribing opiates to Patient B.

12           46. In or around January 2017 to December 2019, Respondent committed negligence in  
13 the course of his care and treatment of Patient B in that prior to initiating prescribing of chronic  
14 pain medications on a regular basis, Respondent failed to properly perform risk stratification  
15 (determining the patient's risk of drug addiction and aberrancy), by failing to, among other things,  
16 perform a psychological evaluation assessing risks of addictive behaviors by using a set of  
17 questionnaire such as Opioid Risk Tool (ORT), SOAPP-R, or PHQ-9, failing to make a possible  
18 referral to psychiatry physicians, if Patient B shows above average risk of addiction, and failing to  
19 closely monitor with regular urine drug testing and/or consultations with a state prescription drug  
20 monitoring program (PDMP) such as CURES reports.

21           47. In or around January 2017 to December 2019, Respondent committed negligence in  
22 the course of his care and treatment of Patient B by failing to recognize Patient B's elevated risks  
23 for addiction, given Patient B's anxiety disorder and illicit marijuana usage.

24           48. In or around January 2017 to December 2019, Respondent committed negligence in  
25 the course of his care and treatment of Patient B by failing to offer and/or failing to document  
26 having offered a multidisciplinary pain management approach including, but not limited to,  
27 surgical orthopedic consultation, pain management consultation, cognitive behavioral therapy

28       ///

1 with mental health, physical therapy, and primary care coordination, which may reduce  
2 Patient B's addiction risks, while adequately treating his pain syndrome.

3 49. In or around January 2017 to December 2019, Respondent committed negligence in  
4 the course of his care and treatment of Patient B by failing to adequately obtain routine regular  
5 urine toxicology testing and/or failing to adequately check CURES reports.

6 Concurrent Usage of Benzodiazepines and Opiates

7 50. In or around January 2017 to December 2019, Respondent committed negligence in  
8 the course of his care and treatment of Patient B by prescribing benzodiazepine(s) and opiate(s)  
9 concurrently, from January 2017 to June 2018, without proper indication.

10 Medical Record-Keeping

11 51. In or around January 2017 to December 2019, Respondent committed negligence in  
12 the course of his care and treatment of Patient B by failing to document functional assessment(s)  
13 of narcotic therapy, failing to document relevant physical examination findings, if any, and failing  
14 to document the dosage and proper indication of the long-term alprazolam (Xanax) therapy.

15 **Patient C**

16 52. In or around 2018, Respondent began rendering medical care and treatment to  
17 Patient C, an adult patient with a history of ailments including, but not limited to, anxiety  
18 disorder.

19 53. On or about February 7, 2018, Patient C presented to Respondent. In his progress  
20 note for the encounter, Respondent documented or caused to be documented that Patient C had a  
21 history of severe anxiety and wanted to raise the dosage of her Xanax (alprazolam).  
22 Respondent documented or caused to be documented that Patient C was at the time taking one  
23 alprazolam 0.25 mg tablet three times per day.

24 54. On or about February 7, 2018, Respondent increased Patient C's prescribed  
25 alprazolam dosage to one alprazolam 2 mg tablet two times per day.

26 55. Respondent failed to conduct an adequate evaluation of Patient C's anxiety illness  
27 prior to increasing the patient's alprazolam dosage to approximately 4 mg daily.

28 ///



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**THIRD CAUSE FOR DISCIPLINE**

**(Prescribing, Dispensing, or Furnishing of a Dangerous Drug without an Appropriate Prior Examination and a Medical Indication)**

63. Respondent has further subjected his Physician's and Surgeon's Certificate No. 36345 to disciplinary action under sections 2227 and 2234, as defined by section 2242, of the Code in that he prescribed, dispensed, or furnished a dangerous drug on one or more occasions without an appropriate prior examination and a medical indication, as more particularly alleged in paragraphs 11 through 62, above, which are hereby incorporated by reference and realleged as if fully set forth herein.

**FOURTH CAUSE FOR DISCIPLINE**

**(Repeated Acts of Clearly Excessive Prescribing)**

64. Respondent has further subjected his Physician's and Surgeon's Certificate No. 36345 to disciplinary action under sections 2227 and 2234, as defined by section 725, of the Code in that he committed repeated acts of clearly excessive prescribing, furnishing, dispensing, or administering of a drug or treatment, as more particularly alleged in paragraph 11 through 62, above, which are hereby incorporated by reference and realleged as if fully set forth herein.

**FIFTH CAUSE FOR DISCIPLINE**

**(Failure to Maintain Adequate and Accurate Records)**

65. Respondent has further subjected his Physician's and Surgeon's Certificate No. A 36345 to disciplinary action under sections 2227, 2234 and 2266 of the Code, in that he failed to maintain adequate and accurate records relating to the provision of services to Patient A and Patient B, as more particularly alleged in paragraphs 11 through 62, above, which are incorporated by reference as if fully set forth herein.

**SIXTH CAUSE FOR DISCIPLINE**

**(General Unprofessional Conduct)**

66. Respondent has further subjected his Physician's and Surgeon's Certificate No. A 36345 to disciplinary action under sections 2227 and 2234 of the Code, in that he has engaged in conduct which breaches the rules or ethical code of the medical profession, or conduct

1 which is unbecoming to a member in good standing of the medical profession, and which  
2 demonstrates an unfitness to practice medicine, as more particularly alleged in paragraphs 11  
3 through 51, above, which are hereby incorporated by reference as if fully set forth herein.

4 **DISCIPLINARY CONSIDERATIONS**

5 67. To determine the degree of discipline, if any, to be imposed on Respondent Mark  
6 Scheier, M.D., Complainant alleges that in a prior disciplinary action entitled *In the Matter of the*  
7 *Accusation Against Mark Scheier, M.D.* before the Medical Board of California, in Case Number  
8 800-2017-031603, effective March 20, 2020, Respondent's license was placed on probation for  
9 five (5) years for gross negligence, repeated negligent acts, prescribing, dispensing, or furnishing  
10 of a dangerous drug without an appropriate prior examination and medical indication, repeated  
11 acts of clearly excessive prescribing, failure to maintain adequate and accurate records, and  
12 violation of medical practice act. That decision is now final and is incorporated by reference as if  
13 fully set forth herein.

14 68. On or about May 19, 1998, in another prior action, the Board issued Decision No. 11-  
15 96-61601 (the "Decision"), which is hereby incorporated by reference and alleged as if fully set  
16 forth herein, wherein the Board found that Respondent committed repeated negligent acts,  
17 incompetence, unprofessional conduct, and failed to keep accurate or complete records in  
18 rendering medical care and treatment to two pregnant female patients. The decision revoked  
19 Respondent's Physician and Surgeon's Certificate No. A 36345, revocation stayed, and placed  
20 Respondent on four years' probation. Probation conditions imposed on Respondent included, but  
21 were not limited to, completion of a physician assessment and clinical education program of at  
22 least three days and including appropriate patient chart documentation, practice monitoring, and  
23 completion of an ethics course. By a subsequent Board decision on or about March 1, 2001, a  
24 Petition for Penalty Relief filed by Respondent was granted and his probation was terminated  
25 effective March 30, 2001.

26 ///

27 ///

28 ///


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**PRAYER**

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Medical Board of California issue a decision:

1. Revoking or suspending Physician's and Surgeon's Certificate No. 36345, issued to Respondent Mark Scheier, M.D.;
2. Revoking, suspending or denying approval of Respondent Mark Scheier, M.D.'s authority to supervise physician assistants and advanced practice nurses;
3. Ordering Respondent Mark Scheier, M.D., to pay the Board the costs of the investigation and enforcement of this case, and if placed on probation, the costs of probation monitoring; and
4. Taking such other and further action as deemed necessary and proper.

DATED: SEP 13 2022

  
\_\_\_\_\_  
WILLIAM PRASIFKA  
Executive Director  
Medical Board of California  
Department of Consumer Affairs  
State of California  
*Complainant*

SD2022801251  
83588828.docx